CYAD-211 is an allogeneic (donor) CAR T Cell therapy that targets the B-cell maturation antigen (BCMA) chimeric antigen receptor.

SparkCures ID 389
Developed By Celyad Therapeutics
Generic Name CYAD-211
Treatment Classifications
Treatment Targets

Clinical Trials

Published Results

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

June 11, 2021

Safety and tolerability data:

Of the six patients dosed at the first two dose levels (30×106 and 100×106 cells per infusion):

  • No dose limiting toxicity (DLT), Graft-versus Host disease (GvHD) or CAR T-cell-related encephalopathy syndrome (CRES) were observed in the first two dose cohorts.
  • One cytokine release syndrome (CRS) Grade 1 (fever) requiring hospitalization occurred 10 days post CYAD-211 administration in patient 1 (dose level 1) who achieved a partial response (PR).
  • One patient experienced an anemia adverse event (Grade 3) and neutropenia (Grade 4) possibly related to CYAD-211.

Clinical activity:

Of the five evaluable patients at the first two dose levels (30×106 and 100×106 cells per infusion):

  • Two patients achieved a PR. Both patients were ‘triple-therapy exposed’ (previously treated with an immunomodulator (IMiD), a proteasome inhibitor and an anti-CD38 antibody).
  • The three additional patients had stable disease (SD).

Cell kinetics:

  • CYAD-211 cells were detected by PCR-based methods in all six patients from dose cohorts 1 and 2.
  • Cell engraftment was seen in all three patients at dose level 2 at a similar magnitude. In addition, preliminary data suggest that all patients in dose level 2 showed deep lymphodepletion. Across dose level 1, the depth of lymphodepletion appears to correlate with the degree of observed systemic CAR T engraftment.

Next steps:

  • Enrollment in dose cohort 3 (300×106 cells per infusion) is ongoing.
  • Additional clinical data from the dose escalation trial are expected during second half 2021.
  • shRNA technology platform to be highlighted at upcoming virtual R&D Day in Q3 2021.